Home › Therapeutic areas › Oncology › Cholangiocarcinoma
Cholangiocarcinoma (10 companies)
Companies with an active program in Cholangiocarcinoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | $186M | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $503M | 10 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | $477M | 7 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | $106M | 7 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $4.11B | 4 |
| REPL | Replimune Group | Oncology | 1 | Approved | $2.05B | 5 |
| SMMT | Summit Therapeutics | Oncology | 1 | NDA Submitted | $13.1B | 6 |
| TYRA | Tyra Biosciences | MetabolicOncology Rare | 1 | Phase 2 | $1.26B | 5 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $2.10B | 11 |
No companies match.